Endogenous uterine prostaglandin levels were monitored in the cycling rat and prostaglandins of the F-type were found to rise at proestrus when estrogen levels have been shown to be maximal. Evidence that this is an estrogen-induced event is furnished by the finding that estradiol-17fl caused a similar rise in prostaglandin F levels in uteri of ovariectomized rats, an action blocked by coadministration of progesterone. Examination of in vitro prostaglandin synthetase by uterine microsomal fractions from cycling rats and estrogen-treated ovariectomized rats revealed that the action of estrogen to control prostaglandin synthesis in a directional manner is accomplished, at least in part, by regulation of the prostaglandin synthetase complex, resulting in a patterned alteration in the ratio of prostaglandin F to prostaglandin E. These results demonstrate that prostaglandins are involved in the expression of estrogen action in the rat uterus.
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Estrogen administration has been shown to effect the release of prostaglandin F2a (PGF2a) into uterine fluids of the guinea pig (1) and monkey (2) . This prostaglandin, which has a potent contractile effect on the isolated uterus, has been identified in sheep as the luteolytic agent produced by the uterus which subsequently acts on the ovary to bring about luteal regression (3) . Estrogen administration has also been shown to be associated with uterine hyperemia (4) . Such hyperemia has been related to elevations in prostaglandin E (PGE) levels (5, 6) . These findings, plus new data demonstrating the existence of receptors unique to PGE1 and PGF2, in the uterus (7) and corpus luteum (8, 9) , pose the possibility that PGEs and PGF2a,, produced in the uterus as a consequence of estrogen action, play distinctly different roles in the reproductive processes.
Recently, the action of estrogen on the uterus of the ovariectomized rat has been shown to be associated with a rise in guanosine 3': 5'-cyclic monophosphate (cyclic GMP) (10) , an observation strengthened by the finding that cyclic GMP is maximal in the normal cycling rat at proestrus (10) , a time when estrogen levels reach their peak value (11 (12, 13) , estrogen itself exhibits no such acute contractile action on the isolated uterus. Thus, in view of the demonstrated ability of estrogen to trigger the production of both cyclic GMP and PGF by this organ, we were prompted to examine these events in more detail.
Emphasis was placed on the estrogen-regulated biosynthesis of prostaglandins E and F, as well as the interrelationships between these prostaglandins and adenosine 3': 5'-cyclic monophosphate (cyclic AMP) and cyclic GMP. The results of these studies are the substance of this report. Female Charles River rats (150-250 g) were used throughout these studies. The stages of their estrus cycle were determined by microscopic examination of vaginal smears. Castrated animals were ovariectomized 1-4 months prior to experimentation. Steroids were administered as solutions in sesame oil; indomethacin was administered as a uniform suspension in sesame oil. All animals were injected and subsequently decapitated while anesthetized with Metofane®.
MATERIALS AND METHODS

Estradiol
Immediately following decapitation and exsanguination, the uteri were denuded of fat, excised and quickly frozen in liquid Freon 12 at Separation and Determination of Cyclic Nucleotides. A trace amount (3000 cpm) of either tritiated cyclic AMP or cyclic GMP, both purified on Dowex-1, was added to 3 ml aliquots of cold 10% trichloroacetic acid for recovery purposes. The frozen tissue was transferred to the acid solution and sonicated in a Polytron (PT 10ST) homogenizer at a pulse frequency of 7300 Hz for 30-60 sec. The insoluble material was removed by centrifugation and analyzed for protein content. The supernatant fraction was extracted with three 5 ml portions of diethyl ether to remove the trichloroacetic acid and then chromatographed in the following manner. The solution was applied to a 0.5 cm X 0.5 cm column of dry Baker neutral aluminum oxide (17, 18) . The eluate was allowed to flow directly onto a second column (0.5 cm diameter X 2.5 cm) of Bio-Rad AG 1-x8 (100-200 mesh) in the formate form and this eluate discarded. The cyclic AMP was eluted by passing 4 ml of 1 N HCOOH over the aluminum oxide column and onto the AG 1-x8 column. Elution was continued with 4 ml of 1 N HCOOH over the AG 1-x8 column only, and the two 4 ml eluates containing cyclic AMP were pooled. Cyclic GMP was next eluted with 12 ml of 4 N HCOOH over the AG 1-x8 column only. All eluates were taken to dryness on a Buchler Evapo-Mix at 500, then placed under pump vacuum for 10 min at room temperature to remove residual formic acid. Cyclic AMP was determined by the Gilman procedure (19) .
Cyclic GMP was measured by a modification of the radioimmune assay of Steiner et al. (20) . The residue was dissolved in 1.0 ml of 40 mM Tris-HCl, pH 7.5, containing 2 mM Mg-SO4. An aliquot was counted in a Packard liquid scintillation counter to calculate recovery. Of four 100 Al aliquots incubated at 300 for 1 hr, two were incubated with phosphodiesterase and then all were heated at 950 for 3 min. 1251I-Labeled antigen, antiserum and 50 mM sodium acetate buffer, pH 6.2 (final volume 500,ul) were added to the cooled tubes and allowed to equilibrate overnight (15-20 hr) at O°. Each sample was diluted with 3 ml of cold 50 mM sodium acetate buffer and immediately poured over a HAWP 02500 (0.45 Am) Millipore filter. The sample tube was washed twice with 3 ml of the same buffer and the washings passed through the filter. The filter was finally washed with an additional 3 ml of buffer. The radioactivity of the antigen-antibody complex retained on the filter was determined directly in a Packard gamma counter. The cyclic GMP measurements include corrections for phosphodiesterase hydrolysis, and the mass of the added tritiated cyclic GMP.
Preparation of 1Microsomes. Uteri were homogenized (1 part tissue/3 parts buffer) in 0.125 M Na-EDTA buffer (pH 8.3) in a Kontes® all-glass homogenizer at 4°. The homogenates were centrifuged for 10 min at 10,000 X g in an International (model PR-2) refrigerated centrifuge. The supernatant phases were then centrifuged for 2 hr at 105,000 X g in a Beckman (model L2-65B) ultracentrifuge. The pellets were taken up in Changes in uterine prostaglandin levels during the estrus cycle of the rat. Animals were sacrificed at the stages indicated and prostaglandins were extracted and measured as described. PGF levels rose significantly at proestrus as compared to metestrus (P < 0.05) and diestrus (P < 0.001). The difference between estrus and proestrus was not significant although that between estrus and diestrus was significant (P < 0.001). The graph shows mean values 4SEM, with the number of observations in parentheses.
0.125 M Na-EDTA (pH 8.3) buffer to a final protein concentration of about 3 mg/ml, and rehomogenized to disperse the microsomes.
Prostaglandin Synthetase Incubation. The reaction mixture consisted of 500,ug of bovine serum albumin (Pentex, fraction V), 5 X 10-4 M hydroquinone, 2 X 10-3 M reduced glutathione, 3 X 10-5 M arachidonic acid, and 0.5 ml (about 1.5 mg of protein) of the microsomes in a final volume of 1.0 ml of Na-EDTA buffer (pH 8.3). After incubation for 30 min at 370 in a Dubnoff shaker, the reaction was terminated by the addition of 1.0 ml of 0.12 M citric acid. Tritiated PGEI and PGFia were added for recovery. The PG extractions and radioimmune assays were performed as described in a section above.
RESULTS
Changes in uterine prostaglandin levels during the estrus cycle
Endogenous levels of PGs were monitored in rats during stages of the estrus cycle - (Fig. 1) . PGF levels at metestrus and diestrus were similar and low, but increased rapidly at proestrus to a value 4-fold greater. The concentration of PGF at estrus continued to exceed that at metestrus and diestrus but proved to be more variable during this stage of the cycle. In contrast, uterine levels of PGE remained relatively constant throughout the cycle with only a small increment occurring at proestrus.
Effects of estradiol and progesterone on uterine prostaglandin levels Ovariectomized rats were treated with estradiol-17,B benzoate days. Uteri were removed 3-4 hr after the final injection. It is noteworthy that endogenous PGE levels rose at least 10-fold following ovariectomy; subsequent estrogen treatment resulted in a decrease in PGE with a concomitant elevation in PGF to levels at least 3-fold higher than those routinely observed at proestrus (Fig. 2) . In some instances an increase in total prostaglandins occurred as a consequence of estrogen action, but the rise in PGF and depression in PGE were consistent observations. Administration of progesterone (4 mg in oil administered subcutaneously) for 3 consecutive days had no effect on PGF levels, although it appeared to depress PGE levels (data not shown). Progesterone, coadministered with estradiol, completely blunted the estrogen-induced stimulation of PGF.
Effects of indomethacin upon uterine PG and cyclic nucleotide levels Administration of indomethacin (1 mg daily) subcutaneously with estradiol antagonized the estrogen-induced rise in uterine PGF (Fig. 3A) and actually lowered both PGE and PGF to below control values. This prostaglandin synthetase inhibitor did not block the estrogen-stimulated rise in cyclic GMP levels (Fig. 3B) . The apparent stimulatory action of indomethacin upon cyclic GMP levels may be due to its action as a cyclic nucleotide phosphodiesterase inhibitor. In any event, the rise in cyclic GMP was not statistically significant.
Changes in uterine prostaglandin synthetase activity during the estrus cycle It is evident from the data in Table 1 The microsomal fractions from uteri from normal cycling rats were evaluated for the ability to convert arachidonic acid to prostaglandins. Cofactor concentrations, buffer, and incubation conditions were as described in the text. Prostaglandins were isolated and analyzed by radioimmune assay.
clic GMP (10) , are an estrogen-related event, since it is well established that estrogen levels peak at proestrus in the cycling rat (11) . The parallel between PGF and cyclic GMP changes was also observed when progesterone was coadministered with estradiol-17# benzoate to ovariectomized rats. Progesterone completely blunted the stimulatory effect of estrogen on uterine PGF content, and this action is similar to its previously observed prevention of the estrogen-induced increase in cyclic GMP (10) .
It has been suggested that in situations where PGE and PGF have opposing actions, these effects are mediated through cyclic AMP and cyclic GMP, respectively (21) . This concept appears to be true with respect to PG action in certain veins wherein the contractile effect of PGF2a is associated with a rise in cyclic GMP, in contrast to the relaxing action of PGE which is associated with a rise in cyclic AMP (12, 13) . Despite the fact that estrogen is capable of effecting an increase in cyclic GMP levels in the rat uterus in vitro, no acute contractile response is associated with this phenomenon. Furthermore, the alterations of cyclic GMP levels that occur as a consequence of estrogen action are confined chiefly to the endometrium (27) , and prostaglandin synthetase activity is also restricted to the endometrial portion of the rat uterus (22) . The contractile action of the uterus is confined to the myometrial portion of this organ. Thus, the interrelationship between PFG and cyclic GMP would appear to be of an entirely different nature in the action of estrogen upon the uterus as compared to the PGF-induced contractile response. That this is in fact the case is evident by the findings reported here that indomethacin is capable of completely blocking the estrogen-induced rise in uterine PFG levels with no concurrent effect upon the rise in cyclic GMP. It is necessary to conclude, therefore, that the rise in PGF that occurs as a consequence of estrogen action is either independent of or secondary to the rise in cyclic GMP.
That estrogen can alter prostaglandin synthetase per se, resulting in a significant increase in the PGF/PGE ratio, casts doubt upon a current hypothesis (23) that tissue levels of prostaglandins are regulated solely by the availability of sub- The E-and F-type prostaglandins differ qualitatively and quantitatively in their actions on many organs. It has been proposed that these prostaglandins interact with receptors unique to each, thus, resulting in a different series of intracellular events (21, 24) . In such a scheme, the nature of the events triggered would be a function of the amounts of individual prostaglandins present, the number of individual receptors available, i.e., for PGE, PGF, or both. The ability of the estrogen (and progesterone) produced by the ovary to regulate the synthesis of prostaglandins by the uterus in a directional and cyclic manner is consistent with the unique roles played by PGEs and PGF2a in the reproductive processes. One of the initial effects of estrogen upon the uterus is to induce a rapid hyperemia (25) . There is much evidence to strate precursor acids. Although precursor acids are important show that this action of estrogen is prostaglandin-mediated (5) , and studies in the gravid uterus implicate PGEs as those involved in this phenomenon (6) . On the other hand, PGF2a has been identified as the substance produced by the uterus that acts on neighboring ovarian tissue to effect luteal regression and an accompanying depression of progesterone levels (3). The contractile action of PGF2a on the myometrium is a classic phenomenon. Whether the precise levels of the individual prostaglandins determine the nature of the events triggered or whether this is simply a function of the PGF/ PGE ratio, which varies widely in the cycle, remains to be determined. However, it is clear that estrogen and the counter action of progesterone combine to play a central role in regulating uterine prostaglandin as well as regulating cyclic nucleotide levels (10) . Although the role of cyclic GMP in uterine function remains to be established, the involvement of prostaglandins has been implicated in several parameters including parturition, estrus regulation, and uterine blood circulation.
It is evident from the present studies that estrogen is capable of regulating the synthesis of prostaglandins both quantitatively and qualitatively in the uterus of the rat. Contrary to the current concept that availability of prostaglandin precursor acids is the sole factor in controlling tissue levels of PGs, the data reported here offer evidence to show that the enzyme complex, prostaglandin synthetase, is subject to hormonal control in a finely regulated manner. It is evident from these actions of estrogen and the counter action of progesterone, that prostaglandins are involved in the expression of the action of these steroidal sex hormones.
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